# ADVANCEMENT OF POTENT BROAD SPECTRUM ENTEROVIRUS THERAPEUTICS

> **NIH NIH N01** · INTEGRATED RESEARCH ASSOCIATES, LLC · 2022 · $1,499,249

## Abstract

This is a phase II SBIR Contract to develop broad spectrum monoclonal antibodies against enteroviruses. Enteroviruses cause neurological diseases mainly in young children including acute flaccid myelitis (AFM) and Hand Foot and Mouth Disease (HFMD).  There is no therapeutics against these viruses or vaccines against them approved in the US. These viruses are members of picornavirus family, a priority pathogen of NIAID because of their high pandemic potential.

## Key facts

- **NIH application ID:** 10684969
- **Project number:** 75N93022C00016-0-9999-1
- **Recipient organization:** INTEGRATED RESEARCH ASSOCIATES, LLC
- **Principal Investigator:** INGRID PERSSON
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,499,249
- **Award type:** —
- **Project period:** 2022-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10684969

## Citation

> US National Institutes of Health, RePORTER application 10684969, ADVANCEMENT OF POTENT BROAD SPECTRUM ENTEROVIRUS THERAPEUTICS (75N93022C00016-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10684969. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*